Clinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, Pre-Treated Nonsmall Cell Lung Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma
NCT05098210 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, Pre-Treated Nonsmall Cell Lung Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 9, 2022
- Completion date
- November 1, 2028
- Enrollment
- 28 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage iv breast cancer ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, locally advanced cutaneous melanoma, locally advanced mucosal melanoma, metastatic acral melanoma, metastatic conjunctival melanoma, metastatic cutaneous melanoma, metastatic her2-negative breast carcinoma, metastatic hormone receptor-positive breast carcinoma, metastatic lung non-small cell carcinoma, metastatic malignant solid neoplasm, metastatic mucosal melanoma, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, recurrent cutaneous melanoma, recurrent her2-negative breast carcinoma, recurrent hormone receptor-positive breast carcinoma, recurrent lung non-small cell carcinoma, recurrent mucosal melanoma, stage iii lung cancer ajcc v8, stage iv lung cancer ajcc v8, unresectable acral melanoma, unresectable cutaneous melanoma, unresectable lung non-small cell carcinoma, unresectable mucosal melanoma